Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 1;178(9):1182-1189.
doi: 10.1001/jamainternmed.2018.3189.

Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial

Niteesh K Choudhry  1   2 , Thomas Isaac  3 , Julie C Lauffenburger  1   2 , Chandrasekar Gopalakrishnan  2 , Marianne Lee  3 , Amy Vachon  3 , Tanya L Iliadis  3 , Whitney Hollands  3 , Sandra Elman  3 , Jacqueline M Kraft  3 , Samrah Naseem  3 , Scott Doheny  3 , Jessica Lee  1   2 , Julie Barberio  2 , Lajja Patel  2 , Nazleen F Khan  2 , Joshua J Gagne  2 , Cynthia A Jackevicius  4   5 , Michael A Fischer  2 , Daniel H Solomon  2   6 , Thomas D Sequist  7
Affiliations
Randomized Controlled Trial

Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial

Niteesh K Choudhry et al. JAMA Intern Med. .

Abstract

Importance: Approximately half of patients with chronic conditions are nonadherent to prescribed medications, and interventions have been only modestly effective.

Objective: To evaluate the effect of a remotely delivered multicomponent behaviorally tailored intervention on adherence to medications for hyperlipidemia, hypertension, and diabetes.

Design, setting, and participants: Two-arm pragmatic cluster randomized controlled trial at a multispecialty group practice including participants 18 to 85 years old with suboptimal hyperlipidemia, hypertension, or diabetes disease control, and who were nonadherent to prescribed medications for these conditions.

Interventions: Usual care or a multicomponent intervention using telephone-delivered behavioral interviewing by trained clinical pharmacists, text messaging, pillboxes, and mailed progress reports. The intervention was tailored to individual barriers and level of activation.

Main outcomes and measures: The primary outcome was medication adherence from pharmacy claims data. Secondary outcomes were disease control based on achieved levels of low-density lipoprotein cholesterol, systolic blood pressure, and hemoglobin A1c from electronic health records, and health care resource use from claims data. Outcomes were evaluated using intention-to-treat principles and multiple imputation for missing values.

Results: Fourteen practice sites with 4078 participants had a mean (SD) age of 59.8 (11.6) years; 45.1% were female. Seven sites were each randomized to intervention or usual care. The intervention resulted in a 4.7% (95% CI, 3.0%-6.4%) improvement in adherence vs usual care but no difference in the odds of achieving good disease control for at least 1 (odds ratio [OR], 1.10; 95% CI, 0.94-1.28) or all eligible conditions (OR, 1.05; 95% CI, 0.91-1.22), hospitalization (OR, 1.02; 95% CI, 0.78-1.34), or having a physician office visit (OR, 1.11; 95% CI, 0.91-1.36). However, intervention participants were significantly less likely to have an emergency department visit (OR, 0.62; 95% CI, 0.45-0.85). In as-treated analyses, the intervention was associated with a 10.4% (95% CI, 8.2%-12.5%) increase in adherence, a significant increase in patients achieving disease control for at least 1 eligible condition (OR, 1.24; 95% CI, 1.03-1.50), and nonsignificantly improved disease control for all eligible conditions (OR, 1.18; 95% CI, 0.99-1.41).

Conclusions and relevance: A remotely delivered multicomponent behaviorally tailored intervention resulted in a statistically significant increase in medication adherence but did not change clinical outcomes. Future work should focus on identifying which groups derive the most clinical benefit from adherence improvement efforts.

Trial registration: ClinicalTrials.gov identifier: NCT02512276.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Choudhry has received unrestricted research grants to study medication adherence from Sanofi, AstraZeneca, Merck, and Medisafe. Dr Lauffenburger has received salary support for unrestricted research grants from Sanofi and AstraZeneca. No other disclosures are reported.

Figures

Figure 1.
Figure 1.. Study Flow Diagram
Figure 2.
Figure 2.. Medication Adherence by Treatment Group Over Time
See this image and copyright information in PMC

References

    1. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530. doi:10.1097/01.mlr.0000163641.86870.af - DOI - PubMed
    1. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.e7-357.e27. doi:10.1016/j.amjmed.2012.09.004 - DOI - PubMed
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. doi:10.1056/NEJMra050100 - DOI - PubMed
    1. O’Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med. 2006;166(17):1802-1804. doi:10.1001/archinte.166.17.1802 - DOI - PubMed
    1. Viswanathan M, Golin CE, Jones CD, et al. . Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785-795. doi:10.7326/0003-4819-157-11-201212040-00538 - DOI - PubMed

Publication types

MeSH terms

Associated data